Earnings Summary

Bio-techne Corp.’s revenue jumped 4.54% since last year same period to $301.32Mn in the Q2 2023. On a quarterly growth basis, Bio-techne Corp. has generated 2.44% jump in its revenue since last 3-months.

Bio-techne Corp.’s net profit jumped 22.69% since last year same period to $75.48Mn in the Q2 2023. On a quarterly growth basis, Bio-techne Corp. has generated 7.5% jump in its net profits since last 3-months.

Bio-techne Corp.’s net profit margin jumped 17.36% since last year same period to 25.05% in the Q2 2023. On a quarterly growth basis, Bio-techne Corp. has generated 4.94% jump in its net profit margins since last 3-months.

Bio-techne Corp.’s earning per share (EPS) estimates for the current quarter stand at 0.49 - a 6.52% jump from last quarter’s estimates.

Bio-techne Corp.’s earning per share (EPS) estimates for the current year stand at 0.49.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bio-techne Corp.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bio-techne Corp.’s return on equity (ROE) stands at 0.16.

Bio-techne Corp. declared 0.08 dividend per share during the earnings announcement for Q1 2023.